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ABSTRACT 
Schizophrenia is a serious psychiatric disorder that affects 1% of the population. 
Current theories implicate NMDA receptor hypofunction as a contributor to the 
symptomology and pathological alterations in schizophrenia. Cognitive impairments are 
increasingly recognized as not only fundamental to schizophrenia, but the strongest 
predictor of patient functional outcomes. Current antipsychotics do not improve the 
cognitive symptoms of the disorder; however, recent efforts have resulted in the 
identification of novel drug targets. One target is metabotropic glutamate receptors as 
they interact with and modulate NMDA receptors. Another approach focuses on 
dopamine, the neurotransmitter system targeted by traditional antipsychotics. 
Tetrahydroprotoberberines, such as D- and L-govadine, are synthetic compounds 
derived from traditional medicine that have demonstrated efficacy in treating 
schizophrenic symptoms. The present study assessed the effects of CDPPB (a 
metabotropic glutamate receptor 5 positive allosteric modulator), D- and L-govadine, 
and the typical antipsychotic haloperidol on the Paired Associates Learning (PAL) task 
in rats. The PAL task is impaired in patients with schizophrenia, has been adapted for 
use with rodents using touchscreen-equipped operant chambers, and has been 
promoted by MATRICS as a promising behavioural task with the potential to further 
translational health research in schizophrenia. The objectives of this study were: 1) 
examine the effects of acute NMDA receptor antagonism with MK-801 as a model for 
schizophrenia on performance of the PAL task; 2) test the effects of the putative 
antipsychotics, CDPPB and D- and L-govadine on reversing the effects of NMDA 
receptor antagonism on the task; and 3) to compare these novel therapeutics to a 
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classic antipsychotic. Two squads of male Long-Evans rats were trained to perform the 
PAL task in touchscreen-equipped operant chambers. After the rats reached criterion 
the following treatment schedules were divided between the two squads: 1) vehicle 
(10% cyclodextrin; i.p.), and CDPPB (1.0, 3.0, and 10.0 mg/kg, i.p.); or 2) vehicle (10% 
cyclodextrin; i.p.), CDPPB (3.0 mg/kg, i.p.), the NMDA receptor antagonist MK-801 
(0.15 mg/kg, i.p.), and CDPPB with MK-801; or 3) vehicle (50% DMSO; s.c.), MK-801, 
D-govadine (1.0 mg/kg; s.c.), L-govadine (1.0 mg/kg; s.c.) and MK-801 with each 
isomer of govadine; or 4) vehicle (sodium acetate and acetic acid, pH 5.0, s.c.), and 
haloperidol (0.05 and 0.1 mg/kg, s.c.). Acute MK-801 significantly reduced the number 
of trials completed, impaired accuracy, and increased the number of errors in the PAL 
task. CDPPB had no effect on the PAL task and did not improve the MK-801 induced 
impairments. Administration of L-govadine, but not D-govadine, prior to MK-801 
improved accuracy and reduced errors compared to MK-801 alone. L-govadine alone, 
but not D-govadine, reduced total responding compared to vehicle. Haloperidol caused 
a dose-dependent decrease in all activity in the task confounding interpretation of the 
results in regard to cognition. These data establish disruptive effects of acute MK-801 
treatment on PAL task performance and demonstrate that L-govadine is capable of 
cognitive enhancement in a rodent model of schizophrenia.    
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1. INTRODUCTION 
1.1. Cognitive Impairment in Schizophrenia: MATRICS, CNTRICS, and PAL 
Schizophrenia is a chronic psychiatric disorder which affects 1% of the general 
population. Recently characterised as a neurodevelopmental disorder, the etiology of 
schizophrenia is believed to depend on a complex interaction of genetic and 
environmental factors (Lipina et al., 2013). The onset of psychotic symptoms usually 
occurs in young adulthood and can lead to a lifetime of disability (Marshall and 
Rathbone, 2011). Although schizophrenia occurs in both men and women, men tend to 
experience earlier onset, more severe symptoms, and are affected more frequently 
(Champagne et al., 2014). Despite the introduction of neuroleptics in the late 1950s 
which effectively treat schizophrenia’s most well-known symptoms, the hallucinations 
and delusions, patient outcomes are typically poor. It is estimated 80% of schizophrenic 
patients are unemployed and up to 70% are unable to live independently (Tregellas et 
al., 2014). The clinical manifestation of schizophrenia has three main categories of 
symptoms which are recognized as fundamental components of the disease. These are 
the positive symptoms which include hallucinations and delusions, the negative 
symptoms which include blunted affect and emotional flattening, and cognitive 
impairments such as memory and attentional deficits. While past research has been 
heavily driven by focus on the positive symptoms, it is becoming increasingly apparent 
that the negative and cognitive symptoms are highly detrimental to the patient’s quality 
of life, even more so than the positive symptoms (Javitt, 2010;Nutt et al., 2013;Vinson 
and Conn, 2012;Nuechterlein et al., 2004). Importantly, the negative and cognitive 
symptoms are unresponsive to conventional antipsychotic treatment via D2 antagonism 
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(Vinson and Conn, 2012). While there have been claims of atypical antipsychotics 
enhancing cognition, these have been unsubstantiated (Vingerhoets et al., 2013). 
Cognitive impairment is of special clinical concern as deficits are present before the 
onset of psychosis, are stable throughout the course of illness, and are the strongest 
predictor of patient functional outcomes (Tregellas et al., 2014;Nuechterlein et al., 
2004;Young et al., 2009;Green, 2006;Green, 1996). Furthermore, cognitive deficits 
persist even when psychosis is otherwise managed (Young et al., 2009). These data 
indicate a profound need for better understanding of cognitive processes as they apply 
to schizophrenia, as well as the development of treatments capable of improving the 
cognitive deficits.  
The importance of cognitive symptoms to outcomes for those with schizophrenia 
and the dearth of treatment strategies prompted the National Institute of Mental Health 
to create the MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) initiative (Marder et al., 2004). The branch of MATRICS most concerned 
with preclinical research and standardization of rodent cognitive testing was given the 
title CNTRICS (Cognitive Neuroscience Treatment Research to Improve Cognition in 
Schizophrenia) (Young et al., 2009;Bussey et al., 2013). The main goals of MATRICS 
are to catalyse collaboration between academic, industrial, and government institutions 
to increase awareness of cognitive impairment as a core feature of schizophrenia, to 
characterise the nature of the deficits in schizophrenia, develop a standardized 
cognitive testing battery, and ultimately develop improved treatment (Young et al., 
2009;Nuechterlein et al., 2004).  
 3 
 
Cognition refers to a variety of conscious and unconscious mental processes. 
Cognitive processes are vital for normal, functional behavior (Keeler and Robbins, 
2011). Through research catalysed by the MATRICS initiative, seven separable 
cognitive domains were identified as affected in schizophrenia. These seven domains 
are: processing speed, attention and vigilance, working memory, verbal learning and 
memory, visual learning and memory, reasoning and problem solving, verbal 
comprehension, and social cognition (Young et al., 2009). The MATRICS initiative 
continues to develop and scrutinize standardized methods of testing these seven 
domains in both humans and animals. Visual learning and memory is impaired in 
schizophrenia as well as in individuals at high risk of developing schizophrenia, and for 
this reason several behavioral tasks have been explored and chosen as promising 
methods to examine visual learning and memory. Such tasks include the Brief Visual 
Memory Task – Revised (BVMT-R) in which the participant is shown 6 geometric 
designs on a piece of paper for 10 seconds, and then must immediately reproduce the 
designs by drawing 3 times. After a 30 minute delay, the drawings are completed a 
fourth time, followed by the presentation of images where the participant answers ‘yes’ if 
they recognize the image, and ‘no’ if they do not recognize it  (Young et al., 2009). 
Schizophrenic patients are impaired in all aspects of the task which are immediate 
recall; 30 minute delayed recall; and recognition (Schretlen et al., 2007). Another task 
used in humans is the visuo-spatial Paired Associates Learning (PAL) task from 
CANTAB (CAmbridge Neurological Test Automated Battery). The CANTAB PAL task, 
like all CANTAB tasks, is conducted on a touch screen computer. Participants are 
presented with 6-8 white rectangles arranged in a circle on a black screen and allowed 
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to see a geometric image located ‘behind’ each rectangle. After a variable delay, one of 
the geometric images is momentarily flashed in the center of the screen and the 
participant must select the white box in the location that the image was originally 
presented (Bussey et al., 2013;Talpos et al., 2009).  Patients with schizophrenia, 
including first episode psychotics, are impaired at PAL (Donohoe et al., 2008;Wood et 
al., 2002;Chouinard et al., 2007;Aubin et al., 2009;Bussey et al., 2013), task 
performance correlates with symptom severity (Prouteau et al., 2005;Prouteau et al., 
2004;Barnett et al., 2005;Bartok et al., 2005), and high risk individuals are impaired 
before the onset of psychosis (Wood et al., 2002;Bartok et al., 2005;Barnett et al., 
2005). There are other conditions in which PAL is impaired, including 
neurodegenerative diseases such as Alzheimer’s disease and Huntington’s, however 
schizophrenia is the only psychiatric disorder to display a deficit in PAL. Even the very 
similar condition schizoaffective disorder does not cause impairment in PAL (Stip et al., 
2005).  
The touchscreen PAL task has several advantages that make it of particular 
relevance to translational health research. PAL is a visuo-spatial association task that is 
fully automated, non-verbal, and conducted on a touch screen computer. The 
automated computer platform makes it simple and time effective to administer PAL 
amidst a battery of tests in order to develop a comprehensive cognitive profile of each 
participant. The non-verbal component increases relevance to cognitive testing in 
animals where language communication is impossible. Finally, there are preclinical 
adaptations of the PAL task that assess visuo-spatial learning and memory in non-
human primates and rodents. The rodent PAL task is sensitive to manipulation of the 
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hippocampus, by either lidocaine inactivation or local MK-801 infusion (Talpos et al., 
2009). Systemic PCP and amphetamine impair task accuracy and decrease trials 
completed, and both systemic ketamine and PCP show a dose-dependent increase in 
response latencies (Talpos et al., 2014). LSD affects the number of trials completed and 
both response and reward collection latencies but not accuracy (Talpos et al., 2014). 
Furthermore, the CNTRICS initiative has stated that touchscreen visuo-spatial PAL task 
has sufficient evidence to support its recommendation as a promising task to assess 
long-term visual learning and memory in schizophrenia studies. This recommendation 
was driven by relevance to schizophrenia, potential for translation, and practicality 
considerations including amenability to drug testing, however further validation is 
needed (Bussey et al., 2013). The research described in sections 2 – 5 of this thesis 
utilizes the rodent PAL task and an established pharmacological model of schizophrenia 
to further validate the PAL task while also addressing the need for improved therapy by 
examining the effects of novel pharmaceutical compounds.  
 
1.2. Dopamine, Glutamate, and GABA in Schizophrenia and Cognition 
The traditional dopamine (DA) hypothesis of schizophrenia suggests over activity 
of the mesolimbic dopaminergic system as the underlying source of pathology (Vinson 
and Conn, 2012;Javitt, 2010;Lodge and Grace, 2008). This hypothesis is supported by 
the efficacy of typical and atypical antipsychotics in reducing or eliminating the positive 
symptoms of the disorder via antagonism of dopamine receptors, particularly D2 
receptors which are present in high numbers in the striatum and nucleus accumbens 
(NA). Post-mortem studies of schizophrenic patients show increased D2 receptor 
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density and heightened sensitivity to amphetamine challenge indicated by increased DA 
release shown in imaging studies (Vinson and Conn, 2012;Seeman, 1987;Seeman, 
2006). Another consideration is the occurrence of hallucinations and delusions as an 
adverse effect of administering L-Dopa, the precursor to DA, as treatment in 
Parkinson’s disease (Schumacher-Schuh et al., 2013). These data support D2 
hyperfunction in the striatum and nucleus accumbens as relevant in schizophrenia 
pathology. It was later shown that D1 hypofunction in the frontal cortex is also present 
and this prompted revision of the original D2 focused hypothesis (Laruelle, 2014). D1 
hypofunction in the frontal cortex is associated with cognitive impairment and negative 
symptoms which aligns with a more complete depiction of the symptoms of 
schizophrenia, but also indicates the disturbances present are more complex than 
previously thought (Millan et al., 2012;Vinson and Conn, 2012).  
 The first indication of involvement of the glutamatergic system in schizophrenia 
came from observations that antagonism of N-methyl-D-aspartate receptors (NMDAR), 
an ionotropic glutamate receptor, by phencyclidine (PCP), ketamine, and MK-801 
(dizocilpine) produced effects that closely resemble schizophrenia, including specific 
cognitive impairment, when administered to healthy individuals, as well as aggravate all 
categories of symptoms in schizophrenic patients (Vinson and Conn, 2012;Javitt, 
2010;Ghoneim et al., 1985;Krystal et al., 1994). Another consideration is the presence 
of decreased NMDAR binding in unmedicated schizophrenic patients (Pilowsky et al., 
2006). NMDAR activation requires binding of both glutamate and glycine, as well as 
membrane depolarization which then triggers calcium influx through the NMDAR 
channel (Vinson and Conn, 2012). Activation of these channels is necessary for long 
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term potentiation (LTP), a mechanism of synaptic plasticity required for the occurrence 
of learning and memory which implicates their involvement in cognition (Robbins and 
Murphy, 2006). NMDARs are distributed throughout the brain at excitatory synapses 
with a particularly high number in cortical and subcortical regions (Monaghan and 
Cotman, 1985;Monaghan et al., 1988;Ozawa et al., 1998). Particularly relevant to 
schizophrenia are NMDAR-containing glutamatergic projections from the mediodorsal 
thalamus to pyramidal cells in the prefrontal cortex, as well as inhibitory projections in 
the NA. In the thalamocortical circuit, glutamate binds NMDARs on GABAergic neurons 
which synapse onto glutamatergic thalamic neurons which then project to PFC 
pyramidal cells. NMDAR antagonism affects the GABAergic neurons and results in 
decreased inhibition of the thalamic neurons to which they project, and subsequent 
decreased inhibition of the PFC further downstream (Vinson and Conn, 
2012;Moghaddam et al., 1997;Moghaddam and Adams, 1998). NMDAR antagonism via 
ketamine at sub anesthetic doses, but not anesthetic doses, increases extracellular 
glutamate in the PFC which could be related to decreased frontal inhibition. While 
NMDARs are diffusely distributed throughout the brain and present on both GABAergic 
and glutamatergic neurons, GABAergic interneurons have 10-fold greater sensitivity to 
NMDAR antagonists, coupled with elevated levels of the endogenous NMDAR 
antagonist kynurenic acid in schizophrenia. Together, these data provide a possible 
source of NMDAR hypofunction (Coyle, 2012). 
 A lack of brain inhibition as a central feature of schizophrenia is also supported 
by reports of altered GABAergic neurotransmission. GABA abnormalities are well 
documented in schizophrenia and include reductions in parvalbumin (PV)-containing 
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interneurons and reduced glutamic acid decarboxylase (GAD)-1 mRNA with resulting 
decreased GAD67 expression (Akbarian et al., 1995;Lewis et al., 2005;Volk et al., 
2000;Hashimoto et al., 2003), an enzyme required in the synthesis of GABA, in the PFC 
and hippocampus (Lodge and Grace, 2008). This finding can be linked with NMDAR 
hypofunction due to the observation that mice treated repeatedly with ketamine have 
reduced PV and GAD67 due to superoxide generation which reduces inhibitory control 
of pyramidal cells (Zhang et al., 2008). 
 More recent theories have suggested that altered dopamine transmission may 
occur as a result of existing NMDAR alterations. When non-competitive NMDAR 
antagonists are persistently administered to animals, a deficit of DA in cortical regions 
and increased DA in subcortical regions arises (Laruelle, 2014). Furthermore, acute 
ketamine increases amphetamine induced DA efflux in healthy individuals as indicated 
by a reduction in D2 binding potential. Enhanced DA efflux in response to amphetamine 
is observed in human schizophrenic patients (Kegeles et al., 2000). In animal research, 
acute administration of ketamine and PCP increases forebrain DA transmission 
(Jentsch et al., 1997b;Doherty et al., 1980;Bowers, Jr. and Hoffman, Jr., 1986;Deutch et 
al., 1987;Hertel et al., 1995) while chronic PCP reduces frontal DA transmission 
(Jentsch et al., 1998;Jentsch et al., 1997c). PCP increases the firing rate of DA neurons 
(Grunze et al., 1996;French, 1994), and reduces cortical GABAergic function which 
results in enhanced glutamatergic transmission in the prefrontal cortex and ventral 
tegmental area to stimulate mesocorticolimbic DA transmission and enhance locomotive 
behaviour (Grunze et al., 1996;Yonezawa et al., 1998;Moghaddam et al., 1997;Mathe et 
al., 1998;Jentsch et al., 1997a). Non-competitive NMDAR antagonism is a well-
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established animal model of schizophrenia due to its robust induction of symptoms 
isomorphic to the human condition. For this reason, rats treated with acute MK-801 
injection was used as the animal model for the research described in sections 2 – 5 of 
this thesis.   
 
1.3. Modelling Schizophrenia: Measurement and Validity 
 Schizophrenia is a complex disorder that is difficult to model in animals. When 
determining the value of any model in research, validity is an important consideration 
(Nestler and Hyman, 2010). Types of validity include face, etiological, predictive, and 
construct validity. If an animal model appears to replicate aspects of the human 
condition including specific symptoms, it is said to have face validity. Etiological validity 
depends upon the etiology of the human condition and the animal model being identical 
(Young et al., 2009). This presents a considerable challenge in schizophrenia as the 
etiology is largely unknown, although it generally believed to depend on an interaction 
between genetic and environmental factors which contribute to perturbed 
neurodevelopment (Lipina et al., 2013). Predictive validity is the ability of the model to 
make predictions about the human condition. For example, if a drug is able to improve 
cognition in the model and then also improves cognition in human schizophrenic 
patients, the model has predictive validity. Predictive validity can also be reversed to 
provide a positive control for the model. If a drug is known to have an effect in the 
human condition, it should have the same effect when applied to the model (Young et 
al., 2009). A current problem regarding predictive validity and cognitive enhancement in 
schizophrenia is a lack of positive controls as no drug treatments have been reliably 
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successful at improving cognition in humans (Floresco et al., 2005). Construct validity is 
of greater relevance in task design and choice than in determining the quality of an 
animal model as construct validity is maintained when a task measures what it is 
intended to measure, such as visual or working memory (Young et al., 2009).  
Directly measuring many aspects of schizophrenia in rodents is challenging, 
particularly the characteristic hallucinations and delusions that accompany an episode 
of psychosis. Instead, researchers must rely on biochemical changes that correspond to 
hallucinations and delusions in humans as a sign of positive symptoms occurring in an 
animal model. One such biochemical abnormality is increased DA efflux in the ventral 
striatum. This also correlates with hyperlocomotion; therefore, hyperlocomotion has 
been used as a measure of positive symptoms in rodents (O'Tuathaigh et al., 
2013;Moghaddam and Adams, 1998). The negative symptoms present an even greater 
challenge as emotional affect may not be present in rodents to the same extent as 
humans, if at all. Despite these species differences, behavioural tasks such as the 
social interaction task and sucrose preference are used to examine social withdrawal 
and anhedonia, respectively. Assessing the negative symptoms is disadvantaged by the 
lack of positive controls for predictive validity as no current treatment is known to affect 
these symptoms (Ellenbroek and Cools, 2000). As mentioned, the cognitive symptoms 
of schizophrenia also lack a positive control for determining the value of the model and 
task used however, the study of the cognitive symptoms has benefitted from the 
numerous behavioral tasks already in use for assessing animal cognition. A number of 
those tasks have been identified by MATRICS and CNTRICS as viable methods to 
assess the seven cognitive domains impaired in schizophrenia (Young et al., 2009). 
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Additionally, cognitive performance in animals and humans appear to depend on 
analogous circuitry and neural constructs (Jentsch and Roth, 1999). 
Animal models of schizophrenia can be divided into four main categories which 
include pharmacological, genetic, lesion, and neurodevelopmental models (Ratajczak et 
al., 2013). Pharmacological manipulations include systemic injection of NMDAR 
antagonists such as MK-801, ketamine, and phencyclidine. Amphetamine, which 
stimulates DA release, and apomorphine, a DA agonist, are also used to model aspects 
of schizophrenia and are often used to induce hyperlocomotion and disrupt prepulse  
inhibition (PPI) in rodents (Geyer et al., 2001). Neurodevelopmental models of 
schizophrenia incorporate prenatal and neonatal insult as indicated relevant by 
epidemiological studies (Rees and Harding, 2004;Rees and Inder, 2005).  Such models 
include maternal immune activation (MIA), prenatal methylazoxymethanol acetate 
(MAM) exposure, isolation rearing and maternal malnutrition. Genetic models include 
Neuregulin 1 (NRG1), dystrobrevin binding protein 1 (DTNBP1), and Disrupted in 
Schizophrenia 1 (DISC1) mutations (O'Tuathaigh et al., 2013). An example of a lesion 
model is Neonatal Ventral Hippocampal Lesion (NVHL) which involves a surgical 
intervention on postnatal day 7 (O'Tuathaigh et al., 2013). 
  
1.4. Acute MK-801 Model of Schizophrenia  
A widely used model of schizophrenia is achieved pharmacologically through 
NMDAR antagonism. As previously discussed, systemic administration of non-
competitive NMDAR antagonists ketamine, phencyclidine (PCP), and MK-801 induce 
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symptoms specific to schizophrenia which include all three symptomatic domains in 
humans and heightens symptoms in schizophrenic patients (Krystal et al., 1994). In 
rodents, NMDAR antagonisms via these compounds induces hyperlocomotion (positive 
symptoms), disrupts sucrose preference (negative symptoms), and induces a variety of 
cognitive deficits including impaired spatial memory in an aversive learning task (Fowler 
et al., 2013) and impaired cognitive flexibility in a T maze set shifting task (Stefani and 
Moghaddam, 2010), as well as disrupts pre-pulse inhibition (thalamocortical loop 
dysfunction) (Stefani and Moghaddam, 2010;Fowler et al., 2013). Notably, the MK-801 
model has never been examined in PAL. MK-801-induced hyperlocomotion can be 
reversed by clozapine, an atypical antipsychotic with high efficacy in treating the 
positive symptoms which indicates predictive validity, however there are no drugs 
currently able to affect cognition and thus no positive control for the cognitive symptoms 
(Floresco et al., 2005). NMDAR antagonism as a model of schizophrenia is benefitted 
by the relative ease of administering systemic injections when required, compared to 
models that require surgical intervention such as the neonatal ventral hippocampal 
lesion model. Furthermore, any observed effects can be attributed to NMDAR 
antagonism, as opposed to a broad effect of any number of abnormalities occurring as a 
result of perturbed neurodevelopment in other models. The MK-801 injection model also 
does not require the time investment required to produce other models, such as 
maternal immune activation (MIA). Finally, MK-801 injection allows the psychotic state 
to be induced only when desired, a luxury not available with neurodevelopmental and 
genetic models. This allows rats to be trained on behavioural tasks in a normal cognitive 
state, a valuable consideration given that many tasks require extensive training and it is 
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not known if rats with permanent cognitive deficits are capable of acquiring these tasks, 
and if so, the time it would require. A disadvantage of any pharmacological model lies in 
etiological validity. Schizophrenia is a neurodevelopmental disorder with evidence 
suggesting a role for prenatal and neonatal insult, as well as interplay with genetic 
susceptibility (Piontkewitz et al., 2012;Lipina et al., 2013). These factors are not 
considered in the pharmacological NMDA antagonism model. 
 Section 1.2. introduced the glutamate theory of schizophrenia and described the 
effects of pharmacologically induced NMDAR hypofunction. As previously mentioned, 
this hypothesis originated based on observation that the effects of NMDAR antagonists 
such as MK-801 bear a striking resemblance to schizophrenia (Coyle, 2012;Krystal et 
al., 1994;Ghoneim et al., 1985;Jentsch and Roth, 1999). Systemic administration of MK-
801 to rodents is a well-established animal model of schizophrenia. The effects are 
robust and last several hours following systemic administration (Jentsch and Roth, 
1999). One of the strengths of the MK-801 model is face validity as it produces several 
isomorphic symptoms to schizophrenia. The positive symptoms can be measured by 
proxy indices such as hyperlocomotion. NMDAR antagonism also induces cognitive 
deficits that fit the seven domains identified by MATRICS, particularly those that require 
the frontal lobe (Luby et al., 1959), and negative symptoms such as social withdrawal 
(Jentsch and Roth, 1999).   
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1.5. New Therapeutics for Schizophrenia 
The recent theories implicating a role for NMDAR hypofunction in the pathology 
of schizophrenia have led to novel therapeutics targeting the glutamatergic system. 
While the obvious target for NMDAR hypofunction would appear to be an NMDAR 
agonist, stimulation of NR2B subunit-containing NMDARs is linked to apoptosis (Lai et 
al., 2011), therefore other approaches to modulate the activity of NMDARs have been 
considered. One group of novel targets are metabotropic glutamate receptors 
(mGluRs). mGluRs are G-protein coupled receptors (GPCR) (Niswender and Conn, 
2010) which are categorized into three groups. Group I includes the subtypes mGluR1 
and mGluR5. These are primarily located postsynaptically throughout the prefrontal 
cortex, striatum and hippocampus, making them of interest in cognition and 
schizophrenia (Stefani and Moghaddam, 2010). Group I mGluRs are coupled to Gq/G11 
which, when activated, stimulate phospholipase C (PLC) to trigger hydrolysis of 
phosphotinositides (PI) and increase intracellular Ca2+. Group II includes mGuR2 and 
mGluR3 which are found both pre- and postsynaptically throughout the forebrain where 
they are coupled to Gi/o and their activation inhibits adenylyl cyclase to influence 
voltage-gated ion channels (Petralia et al., 1996;Gu et al., 2008). Finally, Group III 
include mGluR4, mGluR6, mGluR7 and mGluR8 which are found presynaptically and also 
couple to Gi/o. mGluRs have been identified for potential therapeutic benefit in 
schizophrenia, particularly Groups I and II which are present in the relevant circuitry. 
mGluRs provide an attractive option for drug design due to the presence of allosteric 
sites that are not highly conserved between subtypes which allows for allosteric 
modulation with a high degree of specificity (Conn et al., 2009).  
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 Activation of Group II mGluRs stimulates Gi/o to inhibit cAMP formation, inhibit 
voltage-gated Ca2+ channels, and activate K+ channels to hyperpolarize the cell, prevent 
vesicle fusion to the cell membrane and overall decrease the levels of glutamate 
released (Fell et al., 2012). This results in reduced glutamatergic tone in brain regions of 
interest in schizophrenia such as the striatum, the PFC, and hippocampus (Yoshino et 
al., 1996;Battaglia et al., 1997;East et al., 1995;Lovinger and McCool, 1995). 
Psychotomimetics such as MK-801 increase glutamate activity in the PFC by 
disinhibiting the thalamocortical loop at the level of GABAergic neurons in the NA and 
Group II mGluR agonists reverse this effect (Moghaddam and Adams, 1998;Lorrain et 
al., 2003;Marek et al., 2000). Furthermore, a family of Group II mGluR agonists, best 
characterized by LY354740, have been successful at reversing psychotomimetic-
induced impairments at the behavioral level, however there are variations between 
different behaviour paradigms, animal models, and animal strains (Conn et al., 
2008;Cartmell et al., 1999;Imre et al., 2006b;Imre et al., 2006a;Monn et al., 1997;Profaci 
et al., 2011). In a neurodevelopmental animal model of schizophrenia in which social 
isolation induces hyperactivity, disrupts PPI, and impairs novel object recognition, 
LY404039 reversed hyperactivity (Fabricius et al., 2011), and LY379268 reversed 
hyperactivity, PPI impairment, and novel object recognition impairment (Jones et al., 
2011). Currently, several Group II mGluR agonists have been involved in ongoing 
clinical trials with mixed results (Kinon et al., 2011;Patil et al., 2007). 
 mGluR5, a Group I mGluR, has also been chosen as a promising novel 
therapeutic target for schizophrenia as its activation increases excitation of midbrain 
GABAergic neurons to restore inhibitory regulation to the thalamocortical pathway and 
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PFC and correct the effects of NMDAR hypofunction (Vinson and Conn, 2012). mGluR5 
are involved in regulating the activity of NMDARs. One mechanisms of this regulation is 
NMDAR positive modulation through PKC phosphorylation and tyrosine kinase 
phosphorylation (Lu et al., 1999;Collett and Collingridge, 2004;Kotecha et al., 2003). 
Likewise, NMDAR activity activates calcineurin which dephosphorylates mGluR5 as a 
PKC phosphorylation site (Alagarsamy et al., 1999). Furthermore, NMDAR and mGluR5 
are physically linked via binding and scaffolding proteins (Ehlers, 1999). More 
specifically, mGluR5 bind Homer proteins, and Homer proteins can cluster with PSD-95 
through the postsynaptic density Shank protein. Finally, PSD-95 interacts with NMDAR 
(Fagni et al., 2004;Naisbitt et al., 1999;Tu et al., 1999). As previously stated, NMDAR 
are critical for LTP, a process necessary for normal memory function which occurs 
through up-regulation of membrane proteins. mGluR5 knockout mice show less 
NMDAR-mediated hippocampal LTP and are impaired in NMDAR-dependent learning 
tasks (Jia et al., 1998;Lu et al., 1997). These data provide evidence for a role of mGluR5 
in cognition, particularly learning and memory. Drug design has focused on the 
development of allosteric modulation at these receptors as stimulating the receptor 
directly via agonists induces long term depression (LTD) and seizure activity in 
hippocampal slices and in vivo (Wong et al., 2005).   
 
1.6. CDPPB 
CDPPB, 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide, is an mGLuR5 
positive allosteric modulator (PAM), the first of such compounds to allow for in vivo 
administration due to improved solubility, increased potency, and improved ability to 
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enter the central nervous system compared to earlier compounds (Lindsley et al., 
2004;Kinney et al., 2005;Chen et al., 2007). CDPPB interacts with the MPEP site on 
mGluR5, is mGluR5 selective, and does not interact with any of 175 proteins that 
commonly interact with drugs (Chen et al., 2007). CDPPB reduces amphetamine-
induced hyperlocomotion and amphetamine-induced PPI disruption in rats (Kinney et 
al., 2005). Hyperlocomotion is due to increased DA in the ventral striatum and is 
associated with the positive symptoms of schizophrenia, while disrupted PPI indicates 
abnormalities within the thalamocortical pathway (Alsene et al., 2011). CDPPB also 
reverses MK-801 induced disruption of sucrose preference in rats, a trait relevant to the 
negative symptoms of schizophrenia (Vardigan et al., 2010). These data indicate 
promise for CDPPB, and mGluR5 activity enhancement in general, in treating symptoms 
of schizophrenia.  
LTP and LTD are both critical for the proper formation of memories. In order for 
CDPPB to have potential as a cognition enhancer, it must not disproportionately 
influence LTP or LTD, as that could have negative effects on cognition (Vinson and 
Conn, 2012). An analogue of CDPPB known as VU29 has been examined for such 
effects at the Schaffer collateral-CA1 synapse following afferent-stimulation induced 
LTP and LTD. VU29 enhanced both LTP and LTD without altering the presynaptic 
activity necessary for each type of synaptic plasticity to occur. Furthermore, CDPPB and 
ADX47273, a functionally distinct mGluR5 PAM, improved performance in the Morris 
water maze task in mice, suggesting efficacy as a cognitive enhancer (Vales et al., 
2010;Liu et al., 2008;Chan et al., 2008;Darrah et al., 2008;Uslaner et al., 2009). These 
data provide another indication of the potential for mGluR5 receptor enhancement via 
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such compounds as CDPPB in the treatment for schizophrenia as cognitive impairment 
remains unmanaged with current treatment options (Vinson and Conn, 2012).  
 
1.7. Govadine  
 Govadine is a synthetic compound from the family of tetrahydroprototerberines 
which exists in two isomers, D- and L-govadine. This putative antipsychotic provides a 
dramatic contrast to CDPPB as its effects are predominately within the DA system 
opposed to the glutamatergic system. While relatively little is known about govadine, 
recent studies have indicated efficacy in improving all three symptomatic domains in 
schizophrenia (Lapish et al., 2014;Lapish et al., 2012). Both isomers have been shown 
to have a higher binding affinity for DA-D1/D5 receptors than DA-D2L receptors, and 
have modest affinity for adrenergic receptors and low affinity for serotonin receptors. 
The D2 binding affinity of L-govadine is greater than that of D-govadine, and L-govadine 
is an antagonist at D2 receptors. Behavioral studies show L-govadine improves 
abnormalities representative of positive symptoms such as amphetamine induced 
hyperlocomotion as well as causes catalepsy and impairs conditioned avoidance 
responding, therefore acting like an atypical antipsychotic. D-govadine improves 
cognition in untreated rats by reducing errors in the spatial win-shift task. Both isomers 
improve measures associated with negative symptoms such as amphetamine-disrupted 
latent inhibition and restore impaired social interaction in the NVHL model. At an 
electrophysiological level, when DA neuron firing is suppressed by quinprole, a D2 
agonist, L-govadine, but not D-, restores firing by suppressing G-coupled inward 
rectifying K+ channels. Microdialysis studies show L-govadine increases DA efflux 
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throughout the PFC and nucleus accumbens while D-govadine only increases DA efflux 
in the mPFC (Lapish et al., 2014;Lapish et al., 2012). 
 
1.8. Hypothesis 
 This thesis seeks to explore cognitive impairment in schizophrenia, specifically 
visual learning and memory using the touchscreen visuo-spatial PAL task, acute MK-
801, and novel putative antipsychotics, CDPPB and govadine. Due to the well 
documented effects of systemic NMDAR blockade causing cognitive impairment 
(Moghaddam and Adams, 1998;Lecourtier et al., 2007;Kegeles et al., 2000;Darrah et 
al., 2008;Stefani and Moghaddam, 2010;Moghaddam et al., 1997), and demonstration 
of intra-hippocampal MK-801 disrupting PAL (Talpos et al., 2009), I hypothesize acute, 
systemic MK-801 will reduce accuracy and increase errors in PAL. Similarly, CDPPB 
has successfully restored performance to control levels in multiple spatial cognitive 
tasks when faced with pharmacologically induced NMDAR hypofunction (Moghaddam 
and Adams, 1998;Lecourtier et al., 2007;Kegeles et al., 2000;Darrah et al., 2008;Stefani 
and Moghaddam, 2010;Moghaddam et al., 1997), therefore I hypothesize that PAL, as a 
hippocampal dependent cognitive task, will utilize overlapping circuitry as the tasks 
previously explored and CDPPB will attenuate MK-801 induced deficits. Finally, D-
govadine has also displayed efficacy as a cognitive enhancer, although it has never 
been examined alongside an NMDAR antagonist such as MK-801. As discussed earlier, 
D1 hypofunction in the PFC is associated with cognitive impairment and D-govadine 
increases DA efflux in the mPFC, presumably increasing potential for D1 binding. Given 
these past results, I hypothesize D-govadine will improve PAL performance when faced 
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with acute MK-801. In contrast, L-govadine acts as an atypical antipsychotic, a class of 
drugs not associated with cognitive enhancement. Despite increasing DA efflux in the 
PFC with potential to combat frontal D1 hypofunction, previous research with L-
govadine has not demonstrated cognitive enhancing abilities (Lapish et al., 2014), thus I 
do not expect L-govadine to improve PAL performance. 
 
2. METHODS 
2.1. Subjects 
Two squads of 16 male Long-Evans rats were used (Charles River Laboratories, 
Quebec, Canada). Rats were single housed in clear plastic cages in a temperature 
controlled environment. Lighting was controlled automatically on a 12:12 hour cycle, 
lights on at 7:00 am and all handling and experimentation occurred within the light 
phase. Rats were food restricted to 85% of their free feeding body weight and 
maintained on a food restricted diet with sufficient intake to support normal growth 
throughout the experiment. All experiments were performed in accordance with the 
Canadian Council on Animal Care and were approved by the University of 
Saskatchewan Animal Care and Use Program and the Animal Research Ethics Board.  
 
2.2. Training Apparatus (refer to Figure 1) 
All training and testing was conducted using 8 touchscreen equipped operant 
chambers from Lafayette Instruments. The apparatus consists of a wooden box that can 
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be latched shut with two clips and contains a fan to circulate air and create background 
noise. The operant chamber is located on a sliding shelf at the base of the wooden box. 
An upper sliding shelf holds the sugar pellet dispenser and a video camera. The video 
camera outputs to a monitor for a live feed of the rat’s activity within the chamber. The 
operant chambers are trapezoidal in shape with the wider end consisting of a touch 
screen monitor. The monitor is covered with a black polycarbonate mask. Masks are 
interchangeable depending on the task being conducted. In this case, the mask has 
three rectangular windows which allow the rats to contact the touchscreen monitor only 
in the areas where the stimuli are presented. Directly below the three windows is a 
spring loaded ‘response shelf’. This forces the rats to intentionally stand and press the 
shelf down in order to contact the touch monitor and make a selection. 
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Figure 1: Touchscreen Apparatus. [A] The full apparatus including the blue wooden 
box which houses the touchscreen-equipped operant chamber on the lower sliding 
shelf, and the food magazine and camera on the upper sliding shelf. [B] The interior of 
the chamber as it is set up during the PAL task. Note the mask with three windows open 
to the touch monitor and the spring-loaded response shelf. The funnel shaped opening 
opposite the touchscreen guides the sugar pellet reward to the food port. [C] The three 
images displayed on the monitor during PAL. The images are ordered in respect to their 
correct window in the task. 
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2.3. Touchscreen Habituation and Pretraining (refer to Table 1) 
All rats were left undisturbed for a minimum 5 days following transport and arrival 
to the animal holding facilities. Prior to training, rats were extensively handled over the 
course of 5 days. On day one of habituation, rats were introduced to transportation to 
the testing room and the testing room itself. Rats were brought from the vivarium to the 
testing room via a push cart and elevator and left undisturbed for 1 hour with all 
equipment running (8 chambers, 2 computers), lights dim, and 5 reward pellets placed 
in each cage. For all other days of training, rats were left undisturbed for 15-20 minutes 
following transport to the testing room before being introduced to the chambers.  
Pretraining protocols were conducted as per the instructions and software that 
accompanies the Lafayette touchscreen chambers with the exception of eliminating the 
optional dPAL Acquisition stage. Pretraining began with two days of habituation in which 
the rats were placed in the chambers with 5 reward pellets in the food port and left 
undisturbed for 30 minutes. Criterion was reached if all pellets were located and 
consumed in that time frame. For all pretraining, each phase was repeated daily until 
criterion was reached. Initial Touch Training consisted of one of three windows on the 
screen being illuminated. The location of the illuminated window was pseudorandom in 
that the same window would not be illuminated for three consecutive trials. If the rat 
touched the illuminated screen, 3 pellets were rewarded. If the illuminated screen was 
not touched, 1 pellet was rewarded. The stimulus remained illuminated for 30 seconds, 
or until the rat touched the screen. Following each trial is a 20 second inter-trial interval 
which began when the rat entered the food port to collect the reward. Criterion was 100 
trials completed in 1 hour. Must Touch Training also involved the illumination of one of 
 24 
 
three windows, however the rat must touch the illuminated window to receive 1 reward 
pellet. There was no reward if the rat touched a blank window. Criterion was 100 trials 
completed in 1 hour. This was followed by Must Initiate Training where the illumination 
of the window had to be triggered by the rat nose poking into the illuminated food port, 
followed by touching the illuminated window, to receive a reward pellet. Criterion was 
100 trials in 1 hour. The final stage of pretraining was Punish Incorrect Training in which 
the rat had to touch the illuminated window to receive a reward. An incorrect touch was 
followed by a 5 second time out and then a correction trial in which the same window 
was illuminated. Correction trials continued until the correct selection was made, 
followed by delivery of a food reward. The 20 second inter-trial interval began when the 
reward was collected. Criterion was 100 trials completed in 1 hour with 80% correct for 
2 days in a row. Following Punish Incorrect, training on the full version of the task could 
begin.      
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Table 1: Timeline of training and treatment events. 
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2.4. dPAL Full Task (refer to Figure 2) 
Rats were presented with two of three images on each trial in a pseudorandom 
order. Each image could appear in any one of the three windows on the touchscreen 
monitor. Of these three windows, each image had a correct location and two incorrect 
locations. The images were flower (f), airplane (a), spider (s), plus a blank window (b), 
and could be presented as f+/s-/b-, f+/b-/a-, b-/a+/f-, s-/a+/b-, b-/f-/s+, a-/b-/s+.  The flower 
was always correct when presented in the left window, the airplane was always correct 
in the middle window, and the spider was always correct in the right window. Selections 
were made by nose poke directly onto the screen. Each correct selection was rewarded 
with a sugar pellet, incorrect selections were punished with a 5 second delay. Following 
an incorrect selection, the rat was given a correction trial in which the same pair of 
stimuli were presented repeatedly until the correct selection was made. Correction trials 
were not included in the number of trials completed or task accuracy which were based 
only on the first presentation of each stimulus pair. Rats were trained on this task until 
performance was stable for a minimum of 3 consecutive days at 90 trials completed in 1 
hour with a minimum of 80% correct.  
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Figure 2: dPAL Full Task Schematic. A flow chart of the events that occur in the PAL 
task. The trial begins with a free food delivery into the illuminated food port located 
opposite the screen. The rat nose pokes into the food port to initiate the trial and a pair 
of stimuli appear on the screen. If the rat makes a correct section (the flower in this 
example), the choice is coded as correct and a food delivery is made. Following an 
inter-trial interval of 20 s, the food port illuminates and the rat may initiate the next trial. 
If the rat makes an incorrect selection, the choice is coded as incorrect the rat is 
punished with a 5 s delay before the same stimuli are presented again. The trials with 
repeated stimuli are known as correction trials, and will repeat until the correct choice is 
made. Note that incorrect selections made in the correction trials are not included in the 
accuracy measurement and the number of correction trials are not included in trials 
completed which is instead based on the first presentation of the stimuli only. Also, a 
trial is considered complete once the correct choice is made, either following the first 
presentation or a correction trial. Total trials represents the number of trials plus 
correction trials. 
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2.5. Drug Administration (refer to Table 1) 
Drug treatments were administered following training in a counterbalanced order 
following a within-subjects design with the exception of pilot trials. Squad 1 rats received 
vehicle (10% cyclodextrin), 1.0 mg/kg CDPPB, 3.0 mg/kg, 10.0 mg/kg CDPPB. 
Following this, a subset of rats from squad 1 (n = 7) were tested in a pilot experiment to 
determine optimal doses of MK-801 and CDPPB (data not included in this document). 
Rats were treated with MK-801 a maximum of 2 times at doses of 0.1, 0.15, or 0.2 
mg/kg. Finally, squad 1 rats were treated with vehicle (50% dimethyl sulfoxide), 0.15 
mg/kg MK-801, 1.0 mg/kg D-govadine, 1.0 mg/kg L-govadine, 0.15 mg/kg MK-801 with 
1.0 mg/kg D-govadine, and 0.15 mg/kg MK-801 with 1.0 mg/kg L-govadine. Vehicle, D-, 
and L-govadine were given via subcutaneous injection, MK-801 via intraperitoneal 
injection.  
Squad 2 rats were treated with vehicle (10% cyclodextrin), 0.15 mg/kg MK-801, 
3.0 mg/kg CDPPB, and 0.15 mg/kg MK-801 plus 3.0 mg/kg CDPPB. In a subsequent 
series of treatments, we examined the effects of haloperidol on the dPAL task. 
Haloperidol was dissolved in 1M acetic acid and diluted with 0.5M sodium acetate and 
the final pH was adjusted to 5.0. A subset of 8 rats received vehicle, 0.05 mg/kg 
haloperidol, and 0.1 mg/kg haloperidol. All rats were re-baselined following washout 
periods to ensure adequate proficiency in the dPAL task (performance at criterion for 3 
days in row) before subsequent series of testing began. All drugs were injected at a 
volume of 1 mL/kg except CDPPB which was 2 mL/kg. 
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2.6. Data Analysis 
All data are presented as group means plus or minus the standard error of the 
mean. Dependent measures analysed were accuracy (% correct selections), number of 
trials completed, number of correction trials completed, total trials completed (trials plus 
correction trials), mean correct response latency, mean incorrect response latency, and 
mean reward collection latency. The PAL task is fully automated which eliminates 
observer bias and no data scoring is required. Data analyses were conducted using 
SPSS Version 21. All pharmaceutical manipulations were treated as within-subjects 
factors. Two-way repeated measures ANOVAs were used to analyze the MK-801 with 
CDPPB and MK-801 with govadine data (D- and L-govadine were analyzed separately). 
One-way repeated measures ANOVAs were used to analyze the CDPPB alone and 
haloperidol data. Tukey’s HSD was used for post hoc analysis. 
Two rats from squad 1 were removed due to failure to learn the PAL task and did 
not participate in any drug treatments, reducing the final number of rats in the CDPPB 
alone treatment from 16 to 14. Three more rats failed to reach baseline criterion near 
the end of the govadine treatment schedule despite several attempts to re-baseline and 
did not complete the final treatments. One rat failed to complete any trials when treated 
with L-govadine and was removed from analysis. The final number of rats included in 
the govadine analysis is 12 per drug treatment, however it is not the same 12 rats in 
each treatment group which necessitated analyzing the D- and L-govadine treatments 
separately in order to maintain a true within-subjects design. Finally, the haloperidol 
treatment contained outliers however none were removed from analysis because 
removal would not affect significance, and the overall increased variability and the high 
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standard error of the mean (SEM) reflects the presence of the outliers (refer to Figure 
7). 
 
3. RESULTS 
3.1. The effects of CDPPB on PAL 
          CDPPB was administered to Squad 1 rats via IP injection in three doses (1 
mg/kg, 3 mg/kg, 10 mg/kg) and a vehicle control (10% cyclodextrin). Task accuracy was 
unaffected by CDPPB (Figure 3A; F(3,39)=0.86, p>0.05). There was a significant effect 
of CDPPB on the number of trials completed (Figure 3B; F(3,39)=3.97, p<0.05), and 
post hoc analysis indicates rats treated with the 10 mg/kg dose completed fewer trials. 
Despite this, there was no effect on the number of correction trials (Figure 3C; 
F(3,39)=0.37, p>0.05), or the total number of trials (trials plus correction trials) (Figure 
3D; F(3,39)=2.50, p>0.05). Several latency measures were also included in analysis, 
revealing a significant effect on latency to make a correct decision following initiating the 
trial by nose poke into the food port (Figure 3E; F(3,39)=3.42, p<0.05), with the 10 
mg/kg treated rats taking longer to make a correct response as indicated by post hoc 
breakdown. There was no effect on latency to make an incorrect response (Figure 3E; 
F(3,39)=0.36, p>0.05), and latency to nose poke into the food port to collect the sugar 
pellet following a correct response (Figure 3E; F(3,39)=0.89, p>0.05). 
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Figure 3: The effects of CDPPB on PAL. [A] CDPPB did not affect accuracy (% 
correct). [B] CDPPB significantly reduced the number of trials completed at a dose of 
10 mg/kg. [C] CDPPB did not affect the number of correction trials performed. [D] 
CDPPB did not affect total trials. [E] The 10 mg/kg dose of CDPPB significantly 
increased correct response latency, but did not affect other latency measures.  
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3.2. The effects of MK-801 and CDPPB on PAL 
          Acute injection (i.p.) of CDPPB (3 mg/kg), MK-801 (0.15 mg/kg), CDPPB 
alongside MK-801, and a vehicle control were administered to Squad 2 rats following a 
within-subjects design. The 3.0 mg/kg dose was chosen as it was the highest dose in 
previously examined that did not reduce the trials completed or affect latency. The MK-
801 and MK-801 with CDPPB groups had significantly lower accuracy than the vehicle 
control and CDPPB alone groups due to a significant main effect of MK-801 treatment 
(Figure 4A; F(1,15)=13.21, p<0.01). No main effect of CDPPB (Figure 4A; F(1,15)=1.15, 
p>0.05) and no interaction (Figure 4A; F(1,15)=0.36, p>0.05) were observed. The 
number of trials completed were also significantly reduced in the MK-801 and CDPPB 
with MK-801 groups as shown by a significant main effect of MK-801 treatment (Figure 
4B; F(1,15)=8.84, p<0.01). No main effect of CDPPB (Figure 4B; F(1,15)=3.94, p>0.05) 
and no interaction (Figure 4B; F(1,15)=1.74, p>0.05) were observed. The MK-801 and 
CDPPB treated rats made more errors than when treated with vehicle or CDPPB alone, 
as indicated by significantly increased correction trials. There was a significant main 
effect of MK-801 on the number of correction trials completed (Figure 4C; 
F(1,15)=21.48, p<0.001), but no main effect of CDPPB (Figure 4C; F(1,15)=0.23, 
p>0.05), and no interaction (Figure 4C; F(1,15)=0.29, p>0.05). When trials and 
correction trials were summed to determine the total number of trials completed 
regardless of accuracy there was a significant main effect of MK-801 treatment (Figure 
4D; F(1,15)=19.84, p<0.001) indicating the rats carried out more trials when treated with 
MK-801 and MK-801 with CDPPB compared to vehicle and CDPPB alone. No main 
effect of CDPPB treatment (Figure 4D; F(1,15)=1.27, p>0.05), and no interaction 
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(Figure 4D; F(1,15)=1.31, p>0.05) were observed. Latency to make a correct response 
was differentially affected by MK-801 and CDPPB. There was a significant main effect 
of MK-801 treatment reducing latency (Figure 4E; F(1,15)=9.56, p<0.01), and a 
significant main effect of CDPPB increasing latency (Figure 4E; F(1,15)=8.96, p<0.01). 
No interaction was observed (Figure 4E; F(1,15)=0.03, p>0.05). Incorrect response 
latency decreased due to a significant main effect of MK-801 treatment (Figure 4E; 
F(1,15)=5.70, p<0.05), but there was no main effect of CDPPB treatment (Figure 4E; 
F(1,15)=2.02, p>0.05), and no interaction (Figure 4E; F(1,15)=0.63, p>0.05). Mean 
reward latency was significantly reduced by MK-801 (Figure 4E; F(1,15)=13.53, 
p<0.01), and increased by CDPPB (Figure 4E; F(1,15)=8.44, p<0.05), but there was no 
interaction (Figure 4E; F(1,15)=3.06, p>0.05). Over parameters such as accuracy and 
correction trials, MK-801 impaired cognitive performance in a manner consistent with 
what would be expected in a model of schizophrenia and these deficits were not 
corrected by administration of CDPPB. Some effects of CDPPB on latencies are 
contrary to what was seen with Squad 1, however other measures are consistent with 
the previous experiment. 
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Figure 4: The effects of CDPPB and MK-801 on PAL. [A] MK-801 significantly 
reduced accuracy. CDPPB alone had no effect and did not reverse the deficit. [B] MK-
801 significantly reduced trials completed. CDPPB alone had no effect and did not 
reverse the deficit. [C] MK-801 significantly increased correction trials. CDPPB alone 
had no effect and did not improve the impairment. [D] MK-801 increased the number of 
total trials (total responses). CDPPB had no effect. [E] MK-801 reduced all latency 
measures and CDPPB increased correct response latency. Asterisks were omitted for 
clarity for correct and reward latency.    
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3.3. The effects of MK-801 and D-govadine on PAL  
 Acute injection of MK-801 (0.15 mg/kg, i.p.) and D- and L-govadine (1.0 mg/kg 
(s.c.) were administered alone and in combination (with both govadine isomers kept 
separate), along with a vehicle (50% DMSO). MK-801 treatment significantly reduced 
task accuracy (Figure 5A; F(1,11)=18.30, p<0.01) while there is no effect of D-govadine 
(Figure 5A; F(1,11)=0.44, p>0.05), and no interaction (Figure 5A; F(1,11)=2.14, p>0.05). 
There was a nearly significant reduction of the number of trials completed due to MK-
801 treatment (Figure 5B; F(1,11)=4.79, p=0.051), with no effect of D-govadine (Figure 
5B; F(1,11)=0.00, p>0.05) and no interaction (Figure 5B; F(1,11)=3.63, p>0.05). 
Correction trials were significantly increased by MK-801 treatment (Figure 5C; 
F(1,11)=33.86, p<0.001), but not D-govadine (Figure 5C; F(1,11)=0.56, p>0.05), and no 
interaction was observed (Figure 5C; F(1,11)=1.02, p>0.05). Likewise, MK-801 
significantly increased total trials completed (Figure 5D; F(1,11)=43.79, p<0.001), with 
no effect of D-govadine (Figure 5D; F(1,11)=1.82, p>0.05), and no interaction (Figure 
5D; F(1,11)=0.25, p>0.05). There was no significant effect of either MK-801 (Figure 5E; 
F(1,11)=2.45, p>0.05) or D-govadine (Figure 5E; F(1,11)=0.06, p>0.05) and no 
interaction (Figure 5E; F(1,11)=1.23, p>0.05) regarding correct response latency. 
Similarly, incorrect response latency was unaffected by MK-801 (Figure 5E; 
F(1,11)=3.88, p>0.05) and D-govadine (Figure 5E; F(1,11)=2.32, p>0.05), with no 
interaction (Figure 5E; F(1,11)=2.43, p>0.05). As previously observed, reward latency 
was reduced by MK-801 (Figure 5E; F(1,11)=34.53, p<0.001), but there was no effect of 
D-govadine (Figure 5E; F(1,11)=1.41, p>0.05) and no interaction (Figure 5E; 
F(1,11)=0.01, p>0.05). Overall, D-govadine alone had no effects on PAL performance at 
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any examined parameter, but MK-801 reduced task accuracy, increased correction 
trials and total trials despite a near significant reduction in trials, as well as reduced 
reward latency. D-govadine did not demonstrate efficacy in restoring the MK-801 
induced PAL impairments. 
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Figure 5: The effects of D-govadine and MK-801 on PAL. [A] MK-801 significantly 
reduced PAL accuracy. D-govadine alone had no effect and did not reverse the deficit. 
[B] MK-801 caused a near significant (p=0.51) reduction in trials completed. D-govadine 
alone had no effect and did not reverse the deficit. [C] MK-801 significantly increased 
correction trials. D-govadine alone had no effect and did not improve the impairment. 
[D] MK-801 increased the number of total trials (total responses). D-govadine had no 
effect. [E] MK-801 reduced reward latency, D-govadine had no effect, and no effects 
were observed on the other latency measures. 
 38 
 
3.4 The effects of MK-801 and L-govadine on PAL 
          Acute injection of MK-801 (0.15 mg/kg) and D- and L-govadine (1.0 mg/kg) were 
administered alone and in combination (with both govadine isomers kept separate). PAL 
task accuracy was significantly reduced by MK-801 (Figure 6A; F(1,11)=13.33, p<0.01). 
Furthermore, there was a significant main effect of L-govadine (Figure 6A; 
F(1,11)=13.44, p<0.01), and a significant interaction (Figure 6A; F(1,11)=12.23, 
p<0.01). Post hoc analysis indicated the MK-801 treated group had significantly reduced 
accuracy compared to vehicle, L-govadine, and L-govadine with MK-801. L-govadine 
alone reduced the number of trials completed (Figure 6B; F(1,11)=5.73, p<0.05), while 
there was no effect of MK-801 (Figure 6B; F(1,11)=0.10, p>0.05). A significant 
interaction (Figure 6B; F(1,11)=6.89, p<0.05) was observed for the number of trials 
completed and post hoc analysis revealed the L-govadine treatment causes completion 
of fewer trials than the other treatment groups. There was a significant main effect of 
MK-801 (Figure 6C; F(1,11)=20.94, p<0.01), a significant main effect of L-govadine 
(Figure 6C; F(1,11)=30.49, p<0.001), and a significant interaction (Figure 6C; 
F(1,11)=19.38, p<0.01) regarding the number of correction trials completed. Post hoc 
analysis indicated MK-801 treatment increased correction trials, but L-govadine and 
MK-801 with L-govadine were not different from the vehicle treatment. Regarding the 
total trials completed, MK-801 caused a significant increase (Figure 6D; F(1,11)=14.35, 
p<0.01), but L-govadine caused a significant reduction (Figure 6D; F(1,11)=20.91, 
p<0.01). There was no interaction observed for the total number of trials completed 
(Figure 6D; F(1,11)=0.00, p>0.05). There was no significant effect of L-govadine (Figure 
6E; F(1,11)=3.83, p>0.05), or MK-801 (Figure 6E; F(1,11)=1.36, p>0.05) on correct 
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response latency and no interaction was observed (Figure 6E; F(1,11)=1.14, p>0.05). 
Likewise, there was no significant effect of L-govadine (Figure 6E; F(1,11)=3.78, 
p>0.05), or MK-801 (Figure 6E; F(1,11)=0.28, p>0.05), and no interaction (Figure 6E; 
F(1,11)=0.22, p>0.05) for incorrect response latency. In contrast to the other latency 
measures, L-govadine significantly increased reward latency (Figure 6E; F(1,11)=40.16, 
p<0.001) while MK-801 caused a significant reduction (Figure 6E; F(1,11)=25.99, 
p<0.001). No significant interaction was observed (Figure 6E; F(1,11)=1.23, p>0.05). 
Note the large group mean and SEM for incorrect response latency following treatment 
with L-govadine and L-govadine with MK-801. These increases were driven by a small 
subset of rats with exceptionally high latency, and as it was a minor portion of the 
sample population, their exclusion would not alter the results of the one-way repeated 
measures ANOVA (n.s). This may illustrate heightened sensitivity of some individuals to 
adverse effects of L-govadine. The effect of MK-801 on reward latency was consistent 
with that from Squad 1, however other latency effects were not replicated. Overall, MK-
801 consistently impaired accuracy and increased correction trials across two 
independent samples, as well as increased the total number of trials completed while 
other task measures have more variable results. L-govadine demonstrated efficacy in 
reversing the MK-801 induced impairments in accuracy and correction trials however it 
also reduced the total trials completed. 
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Figure 6: The effects of L-govadine and MK-801 on PAL. [A] MK-801 significantly 
reduced accuracy. L-govadine reversed the deficit but had no effect alone. [B] MK-801 
had no effect on trials completed but L-govadine caused a significant reduction. [C] MK-
801 significantly increased correction trials. L-govadine restored correction trials to 
control levels, but had no effect alone. [D] MK-801 increased the number of total trials 
(total responses) and L-govadine decreased total trials. Asterisks were omitted for 
clarity. [E] MK-801 reduced reward latency and L-govadine increased reward latency 
with no effect on other latency measures. Asterisks were omitted for clarity for reward 
latency. 
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3.5. The effects of Haloperidol on PAL 
          Haloperidol was administered subcutaneously in 2 doses, 0.05 mg/kg and 0.1 
mg/kg, as well as a vehicle control (acetic acid and sodium acetate, pH adjusted to 5.0). 
Haloperidol did not impair task accuracy compared to the vehicle treatment (Figure 7A; 
F(2,14)=2.74, p>0.05), however a significant effect was observed on trials completed 
(Figure 7B; F(2,14)=29.02, p<0.001). Post hoc analysis indicated that treatment with 
both doses reduced trials completed than the vehicle treatment and the two doses differ 
from each other as well, decreasing in a stepwise dose-dependent manner. There was 
also a significant effect of haloperidol on correction trials (Figure 7C; F(2,14)=8.01, 
p<0.01) with post hoc analysis indicating the high dose of 0.1 mg/kg resulted in fewer 
correction trials than the 0.05 mg/kg dose and vehicle, which did not differ. When 
examining the total trials completed, there was a significant effect of haloperidol 
treatment (Figure 7D; F(2,14)=28.63, p<0.001). Post hoc analysis indicated both doses 
of haloperidol treatment reduced total trials compared to vehicle and the two doses 
were significantly different from each other. The latency to make a correct choice was 
not affected by haloperidol (Figure 7E; F(2,14)=3.99, p>0.05), however a significant 
effect of haloperidol was found to increase incorrect response latency (Figure 7E; 
F(2,14)=6.83, p<0.05). Post hoc testing showed rats took significantly longer to make an 
incorrect selection when they received the high dose of 0.1 mg/kg. No effect of 
haloperidol was observed on reward latency (Figure 7E; F(2,14)=1.12, p>0.05). Note 
the high mean and SEM shown in Figure 7E for correct response and reward latency. A 
small subset of rats are responsible for increasing the mean, and this is represented in 
the large SEM. These rats were considered for exclusion from analysis but were 
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ultimately included as their exclusion would not have changed the overall outcome of 
the one-way repeated measures ANOVA (n.s.), as well as to demonstrate the variability 
in sensitivity of individual subjects to the haloperidol treatment. 
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Figure 7: The effects of haloperidol on PAL. [A] Haloperidol did not significantly 
affect accuracy. [B] Haloperidol caused a dose-dependent decrease in the number of 
trials completed. [C] Haloperidol significantly reduced the number of correction trials at 
0.1 mg/kg. [D] Haloperidol caused a dose-dependent decrease in the number of trials 
completed. [E] Haloperidol significantly increased correct and incorrect response 
latency at the 0.1 mg/kg dose with no significant effect on reward latency. 
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4. DISCUSSION 
The present experiments resulted in novel data regarding the MK-801 animal model 
of schizophrenia in the touchscreen visuo-spatial PAL task and the putative 
antipsychotics CDPPB and govadine. No effects of CDPPB were found, either when 
administered alone (Figure 3) or alongside MK-801 (Figure 4), except for a significant 
reduction in the number of trials completed at the 10 mg/kg dose of CDPPB (Figure 3B). 
MK-801 at a dose of 0.15 mg/kg reliably reduced accuracy, increased correction trials, 
and increased total trials across two independent samples (Figure 4ABCD, Figure 
5ABCD, Figure 6ABCD). More variable were the effects of MK-801 on the latency 
measures (Figure 4E, Figure 5E, Figure 6E). D-govadine alone had no effect on any of 
the measured parameters and did not affect the MK-801 induced deficits (Figure 5). L-
govadine alone decreased the total number of trials completed and increased reward 
latency, while also attenuating the MK-801 induced deficits to control levels (Figure 6). 
Haloperidol did not affect PAL accuracy at either examined dose but caused a dose 
dependent decrease in trials completed, correction trials and total trials while increasing 
incorrect response latency at the 0.1 mg/kg dose. Overall, these results indicate that the 
MK-801 model of schizophrenia induces deficits in visuo-spatial PAL, a task that 
measures one of the seven cognitive domains affected in schizophrenia. These data 
further indicate that positive allosteric modulation of mGluR5 and systemic 
administration of D-govadine do not enhance PAL in either untreated rats or those faced 
with a pharmacological challenge via systemic MK-801, however systemic L-govadine 
reversed the MK-801 induced deficits.  
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4.1. Acute MK-801 injection impairs cognitive performance in PAL 
 Systemically administered MK-801 impairs cognitive performance in a variety of 
tasks including recognition memory, set-shifting, and spatial learning and memory 
(Vales et al., 2010) however its effects on performance of the PAL task had never been 
examined until the present study. The dose used in the present experiment is 0.15 
mg/kg is within the typical range for rats (0.1 to 0.3 mg/kg) (Darrah et al., 2008;Stefani 
and Moghaddam, 2010). MK-801 was administered to two independent squads of rats 
and significantly reduced accuracy (% correct), increased correction trials (errors), and 
increased total trials in both squads, but trial number was only significantly reduced in 
squad 2 (Figure 4B). Correction trials follow incorrect selections in which the same pair 
of stimuli are repeatedly presented until the correct choice is made (Figure 2), thus an 
increase in correction trials indicates an increase in perseverative errors. Perseveration 
is usually assessed in set-shifting tasks to refer to the number of times a participant 
reverts to an old strategy despite requiring a new strategy to complete the task or 
receive a reward. However, the definition of perseveration is repetitive maladaptive 
errors, such as repeatedly selecting the same image despite indication that it is 
incorrect or inappropriate as is the case with the visuo-spatial PAL task correction trials. 
Perseveration is a hallmark feature of cognitive impairment in schizophrenia and is 
associated with prefrontal cortex dysfunction (Pantelis et al., 1999) and NMDAR 
hypofunction (Darrah et al., 2008;Stefani and Moghaddam, 2010). The increase in 
correction trials following MK-801 treatment indicates increased relevance of PAL to the 
human condition of schizophrenia, as well as provides another way to assess 
perseveration in a task not requiring cognitive flexibility. 
 46 
 
Total Trials is a novel measure that has not been included in previous PAL 
publications. This is the sum of trials completed, which is a count of how many times a 
rat responded to the first presentation of a stimulus pair (not including correction trials), 
plus correction trials. The total trials measure provides more information as to how the 
rats are spending their time in the touchscreen chamber. Previous work reports a 
decrease in trial number to indicate decreased responding (Talpos et al., 2014), but 
makes no reference to correction trials despite each correction trial also indicating a 
response. As mentioned in section 2, criterion on the PAL task is 90 trials completed in 
60 minutes. The session automatically ends after 60 minutes or 90 trials are completed, 
whichever occurs first. As correction trials are not included in the response count for 
trials completed, when correction trials increase, first-presentation trials will decrease as 
long as the 60 minute time limit is enforced simply due correction trials taking up an 
increased portion of the allotted 60 minutes. Therefore, trials completed alone does not 
fully account for the number of responses made. In this experiment, MK-801 treatment 
increased total trials signifying that MK-801 does not reduce responding (Figure 4D, 5D, 
6D). This does not necessarily indicate that MK-801 increases responding because the 
vehicle treated rats make less errors allowing them to move through the 90 trials more 
quickly, causing the session to end and preventing further responding. Therefore, the 
total trials measure can only indicate if responding is decreased but not if it is increased, 
as whether or not the 90 trials are completed affects the time frame in which responding 
can occur. The knowledge that MK-801 does not reduce the ability of a rat to make a 
response strengthens the argument that the reduction in accuracy and increase in 
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errors is due to cognitive impairment, not other factors such as impaired motor function 
or motivation which could also reduce responding and effort in the task. 
 When assessing a visual based task, it is important to consider the possibility 
that the drug administered may affect visual perception. The effects of various 
pharmaceuticals have been assessed in a touchscreen visual discrimination task and 
found no compelling evidence that either MK-801 or PCP induce selective impairments 
in perception, indicating NMDAR antagonists are appropriate for use in researching 
cognition in visual based tasks (Talpos et al., 2012). 
Overall, these data indicate that NMDAR hypofunction via systemic MK-801 
impairs performance in the PAL task. The cognitive impairment is consistent with what 
is observed in human schizophrenic patients as an increase in perseverative errors 
robustly occurred in both independent squads tested without reducing responding.  
 
4.2. CDPPB alone affects trials completed but not cognitive performance in PAL 
 The results displayed for the vehicle treated rats in Figure 3 are comparable to 
previous studies that examined PAL with the mean accuracy achieved near 90% 
(Talpos et al., 2014;Talpos et al., 2009). The only significant effect of CDPPB alone was 
a reduction in trials completed at the highest administered dose, 10 mg/kg. Previous 
studies have examined motor effects of CDPPB using the rotorod test and open field 
locomotion and no significant locomotor effects were found using doses of up to 30 
mg/kg (Fowler et al., 2013;Stefani and Moghaddam, 2010). Despite no significant 
effects, previous authors have noted that the time required to complete maze-based 
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tasks takes 20% longer when rats receive 10 mg/kg and 30 mg/kg CDPPB than when 
they are vehicle treated (Fowler et al., 2013;Vales et al., 2010). This indicates potential 
for doses of CDPPB 10 mg/kg and higher to affect locomotor ability in some capacity 
that may not be directly measured in an open field locomotor assessment, such as 
reaction time. It is worth noting the highest dose assessed using a rotorod was 5 mg/kg 
(Vales et al., 2010), half of the dose that caused a reduction in trials completed in the 
present experiment. Furthermore, there was no effect on task accuracy or correction 
trials, indicating no negative cognitive effects of CDPPB that could have influenced trials 
completed.  
CDPPB did not affect accuracy or correction trials which is consistent with 
previous research as there are currently no reports of CDPPB alone improving cognition 
in conditions where performance is already high (further specified in section 4.3.). It is 
possible that CDPPB alone could enhance performance in a task with more freedom to 
manipulate the difficulty, such as the touchscreen TUNL task, a non-match to sample 
task in which both the delay between the sample and test phases and the locations of 
the stimuli can be modified to increase difficulty (Oomen et al., 2013). In PAL the vehicle 
treated rats are already performing at a mean of approximately 90% correct which may 
indicate a ceiling effect.  
 
4.3. CDPPB does not reverse MK-801 induced impairments in PAL 
 CDPPB was administered alongside MK-801 at the moderate dose of 3 mg/kg to 
determine if the mGLuR5 PAM would attenuate the MK-801 induced deficits. The only 
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effect of CDPPB was increased correct response latency with no effect on any of the 
measures directly related to cognition, namely accuracy and correction trials. As 
previously mentioned, CDPPB has improved cognition in spatial based tasks. 
Specifically, CDPPB reduced perseverative errors during reversal learning in the 
Barne’s maze (Fowler et al., 2013), enhanced performance in a delayed-alternation T-
maze task at increased delays (Fowler et al., 2013), and reduced MK-801 induced 
impairments in spatial aversive learning with no effect on aversive learning in controls 
(Fowler et al., 2011). CDPPB also restores MK-801 induced deficits in a set-shifting task 
using a T-maze by restoring trials to criterion and perseverative errors to control levels, 
once again with no effect in control animals (Stefani and Moghaddam, 2010). Given that 
CDPPB has repeatedly demonstrated efficacy in improving perseveration due to 
cognitive inflexibility following MK-801 administration but not in the current study 
suggests fundamental differences between two types of perseverative behaviors that 
can both be caused by NMDAR hypofunction. The PAL task is rigid in structure in that it 
requires learning three distinct visuo-spatial associations over a relatively long-term 
training phase. These visuo-spatial associations do not change over the course of 
experimentation which makes PAL different from tasks that assess cognitive flexibility. 
Cognitive flexibility depends on dopaminergic and glutamatergic transmission in the 
medial prefrontal cortex, the major neurotransmitter systems involved in current theories 
of schizophrenia (Javitt, 2010;Coyle, 2012). CDPPB attenuates MK-801-induced 
abnormalities in the mPFC such as increased firing and decreased burst frequency 
(Lecourtier et al., 2007) thus enhanced mGLuR5 activity measurably affects mPFC 
dysfunction due to NMDAR antagonism. This is presumed to underlie the CDPPB 
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related improvements observed in cognitive flexibility tasks. The data collected in the 
current experiment indicate that this same effect is not sufficient when persistent error 
making occurs in a more rigid task setting. A possible explanation of the impairment 
could be that the disturbance observed in the present study is the disturbance of a 
learned habit. PAL is an operant task, the like of which tend to be goal-oriented, but can 
become driven by habit following extended practice (O'Tousa and Grahame, 2014). 
Habitual action relies on the dorsolateral striatum, distinct from the reward-driven 
behaviors dependent on the dorsomedial striatum, however these regions interact in 
reward-driven habit forming (Burton et al., 2014), which could describe the rigid 
touchscreen PAL task. One potential caveat is habitual learning is not impaired in 
schizophrenic patients (Weickert et al., 2002), although no data could be found 
regarding maintenance of an already acquired habit during an episode of psychosis, 
which would be much more relevant to the present study. If PAL does involve habit 
formation, these data may indicate a disruption of habitual behavior in acute psychosis. 
One effect of NMDAR antagonism is increased DA release in the striatum (Jentsch and 
Roth, 1999), providing a potential mechanism of striatal modulation.  However, mGluR5 
are also present in the striatum which raises the question as to why there was no effect 
of CDPPB in correcting these deficits. These data necessitate a closer look at PAL, 
habit development and maintenance, and NMDAR antagonism in the striatum and 
surrounding circuitry. 
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4.4. L-govadine, but not D-govadine, reverses MK-801 induced impairments in PAL 
 Govadine differs greatly from CDPPB as it affects the DA system. When 
combined with acute MK-801 the two govadine isomers produced opposite results with 
L-govadine attenuating the MK-801 deficits (Figure 6) and no effect of D-govadine 
(Figure 5). More specifically, L-govadine restored accuracy (Figure 6A) and correction 
trials (Figure 6C) to control levels when administered with MK-801 while D-govadine 
and MK-801 treated rats did not differ from MK-801 alone for accuracy (Figure 5A) or 
correction trials (Figure 5C). Previous research shows that D- and L-govadine have 
different but complementary effects: L-govadine acts like a typical antipsychotic capable 
of improving positive symptoms, generally attributed to greater efficacy as a D2 
antagonist, while D-govadine is a cognitive enhancer (Lapish et al., 2014), contrary to 
the precognitive effects of L-govadine observed in the present study. The main 
differences between the two isomers are L-govadine’s greater affinity for D1 receptors 
and greater D2 antagonist effects than D-govadine, and L-govadine increases DA efflux 
in the NA (ventral striatum), and throughout the PFC whereas D-govadine is limited to 
the mPFC (Lapish et al., 2014). As previously mentioned, cognitive impairment is 
partially attributed to D1 hypofunction in the PFC (Coyle, 2012). The cognitive 
enhancing effects of L-govadine may be due to increasing DA effux in regions of the 
PFC beyond the mPFC.  
The prospect of PAL involving habitual action was introduced in section 4.3. and 
goal-directed habitual action depends on striatal structures (Burton et al., 2014), 
therefore implicating the involvement of circuitry under greater influence of L-govadine 
due to its unique ability to increase DA efflux in the ventral striatum.  For example, the 
 52 
 
orbitofrontal cortex and ventral striatum feed into circuits involved in habitual behavior 
(Balleine and O'Doherty, 2010). Furthermore, an fMRI study in humans reports activity 
in the OFC and ventral striatum in response to visual stimuli predictive of a food reward, 
which may be of relevance in the visuo-spatial PAL task. Seemingly contradictory 
however, is the ability of NMDAR antagonism to increase DA efflux in the ventral 
striatum (Jentsch and Roth, 1999). Taken together, L-govadine’s action as a D2 
antagonist working in unison with increased DA efflux in the ventral striatum, as a result 
of both its own effect and NMDAR hypofunction, combined with a general increase of 
DA efflux throughout the PFC may create conditions suitable for normal performance in 
the PAL task, restoring accuracy and correction trials to control levels. While the 
systemic injections utilized in this study cannot implicate specific brain regions, these 
data, when considered in light of the discussed work on habitual behavior appear to 
support visuo-spatial PAL containing elements of habit. 
Trials completed and total trials were also differentially affected by D- and L-
govadine, where D-govadine had no effect (Figure 5B, 5D) and L-govadine significantly 
reduced both (Figure 6B, 6D). As described in section 4.2. total trials is a measure of 
total responding, indicating less activity overall following L-govadine treatment. Given 
that L-govadine has effects in the striatum, locomotor impairment due to catalepsy could 
be responsible but this is not likely considering response latencies were not severely 
affected (although there was a slight increase in reward latency). It is worth noting that a 
small number of rats showed exceptionally high response latency when treated with L-
govadine which may indicate individual sensitivity to the drug treatment. While three 
latency measures are calculated by the software, a fourth latency measure is not 
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quantified, and this is the latency to initiate a new trial following reward collection. By 
order of elimination, if the other three latency measures are not abnormally altered, 
latency to initiate a trial must be increased to account for the allotted 90 minute time 
frame. It is possible that L-govadine’s ability to affect the striatum as previously 
mentioned may also have an effect on motivational and goal-directed behavior, as this 
is a function of the dorsomedial striatum (Burton et al., 2014;Balleine and O'Doherty, 
2010), therefore decreasing the total number of responses. 
 
4.5. Haloperidol lowers task activity in a dose-dependent manner. 
 Haloperidol is a typical antipsychotic and potent D2 antagonist. Despite the 
reports of conventional antipsychotics being ineffective in improving cognitive deficits 
(Javitt, 2010;Young et al., 2009;Millan et al., 2012) the success of L-govadine, a drug 
that acts as a D2 antagonist among other previously discussed effects, in improving 
cognitive parameters in PAL prompted further investigation of D2 receptors. While PAL 
accuracy decreased with each increasing dose of haloperidol, no significant effect was 
observed (Figure 7A). Trials, correction trials, and total trials were all reduced in a dose 
dependent manner with the 0.1 mg/kg treatment group completing less than half of the 
total responses as the vehicle group. A significant reduction in correction trials would 
generally be taken as a reduction in errors and therefore cognitive enhancement, 
however in this case the reduced correction trials are proportional to the reduced total 
trials. This severe effect on responding is likely due to the well documented 
extrapyramidal effects of classic antipsychotics which include muscle rigidity known as 
catalepsy (Marrocco et al., 2013). These motor effects confound the ability of the PAL 
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task to provide insights into cognitive effects which may be directly related to D2 
antagonism.  
 
4.6. Limitations and future directions 
 Limitations of the research presented in this thesis include the use of only one 
behavioural task. While the extensive training regimen would have made the addition of 
another task difficult in the given time frame, the PAL task is not able to provide direct 
information on attention or motivation which would have given greater insights into the 
nature of the deficits produced by MK-801 and could have helped explain the decrease 
in total trials seen following L-govadine administration. Future research directions 
include using local infusions to elucidate the brain regions involved in the PAL task. 
Such targets include inactivation of the mPFC and dmSt, followed by more specific 
manipulations such as D1 antagonism in the mPFC in attempt to mimic, and reverse, 
the deficits from MK-801. These studies will help explain why a pro-cognitive effect of L-
govadine, but not D-, was observed. Another future direction is to address the 
aforementioned limitation and repeat the pharmaceutical treatments used in this study 
with other behavioural tasks, such as TUNL and the 5-choice serial reaction time task. 
 
5. CONCLUSION 
This thesis presents novel findings regarding cognitive deficits in a pharmacological 
rodent model of schizophrenia. These data demonstrate the efficacy of acute MK-801 in 
inducing deficits relevant to schizophrenia in a visuo-spatial association task which has 
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been promoted by MATRICS and CNTRICS as a promising technique with translational 
potential. These data further indicate that the mGluR5 PAM CDPPB is not effective at 
restoring the MK-801 induced deficits in PAL. This thesis also contains the first data 
indicating cognitive enhancement due to L-govadine, an effect which may be due to the 
PAL task containing elements of habit. Finally, these data demonstrate the adverse 
effects of haloperidol which confound interpretation of cognitive performance. These 
findings constitute a valuable contribution to the study of cognition and the collaborative 
effort to improve treatment in schizophrenia.  
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